Abstract: A heavy-duty interactive (HDi) system may include a heavy-duty vehicle; a work tool installed on the heavy-duty vehicle; a memory that stores a plurality of patterns representing operation events for the heavy-duty vehicle; a first sensor affixed to the heavy-duty vehicle that collects first sensor data as the heavy-duty vehicle is operated; a second sensor affixed to the work tool that collects second sensor data as the work tool is operated; and a controller operatively coupled to the first sensor, the second sensor, and the memory. The controller may be configured to identify a heavy-duty vehicle operation event by comparing at least one of the first sensor data and the second sensor data with the plurality of patterns in the memory, and associate the work tool with the heavy-duty vehicle based on a comparison of the first sensor data and the second sensor data.

Abstract: A drone launch system includes a canister defining an internal cavity, and a drone positioned within the internal cavity in a stowed state. The drone is configured to be ejected from the canister and transition from the stowed state into a deployed state outside of the canister. A method for launching a drone, the method includes positioning the drone in a stowed state in an internal cavity of a canister, ejecting the drone from the canister, and transitioning the drone into a deployed state after the ejecting operation.

Abstract: A drone launch system includes a canister defining an internal cavity, and a drone positioned within the internal cavity in a stowed state. The drone is configured to be ejected from the canister and transition from the stowed state into a deployed state outside of the canister. A method for launching a drone, the method includes positioning the drone in a stowed state in an internal cavity of a canister, ejecting the drone from the canister, and transitioning the drone into a deployed state after the ejecting operation.

Abstract: The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein.

Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.

Abstract: The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein.

Abstract: Chronic fatigue syndrome and prolonged QT interval are treated using one or more different double-stranded ribonucleic acids (dsRNA).

Abstract: An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human ?-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.

Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.

Abstract: A subset of human patients having chronic fatigue syndrome and impaired physical performance is treated using one or more different double-stranded ribonucleic acids (dsRNA) or other selective agonists of Toll-like receptor 3 (TLR3).

Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.

Abstract: A mixture of ?-interferons (IFN-?) is used in vitro or in vivo as an antimicrobial agent or anticancer agent. It may be administered by topical application to oral or nasal, and/or buccal mucosa to combat the effects of infection by bacteria or protozoa, cancer, or other pathogenic disease process (e.g., autoimmune or neurodegenerative disease).

Abstract: A mismatched double-stranded ribonucleic acid, which is an agonist for Toll-like receptor 3 (TLR3), is used in vitro or in vivo as an antimicrobial agent, antiproliferative agent, and/or immunostimulant. Poly(l:C11-14U) is a more selective agonist of TLR3 as compared to poly(l:C) even though the both double-stranded RNA are structurally analogous.

Abstract: A manually operable device and a method for separating solid waste materials from liquid to be disposed of through a drain, and for reducing the size of pieces of such solid waste materials for more efficient disposal through the drain. A size reduction assembly is manually movable with respect to a stationary body and may include perforated material for catching solid material from a liquid flowing into the drain, and at least one cutting or ripping or abrasion component for reducing the size of pieces of the solid material into smaller pieces that may then pass downward through the drain. In some embodiments the size reduction assembly may be driven downward by pressure from a hand or foot. The reduced-size pieces of material are flushed from the device by liquid draining through the device.

Abstract: The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein.

Abstract: Symptoms of viral infection are mitigated by administering to a subject exposed to a virus a protective or symptom-mitigating amount of a dsRNA and continuing administration until the subject's symptoms have improved.

Abstract: A method, system and apparatus for the monitoring, diagnosis and evaluation of the state of a dynamic drug display system is disclosed. This invention provides for the rapid cognitive grasp of the overall state of drug combination effects with respect to a dynamic system. The system provides for displayed objects, which change in real-time to show the changes of the functions of the system. In particular, this invention is directed to the processing and display of drug data for the use of doctors in the process of monitoring or administering drugs to patients.

Abstract: Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA.